CPRX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 107273 min ago

@ $13.37

Wydano: 14 vas. 2024 @ 21:08

Zwrot: 11.41%

Poprzedni sygnał: vas. 13 - 17:35

Poprzedni sygnał: Sprzedaż

Zwrot: 0.00 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	772 159
Średni wolumen	1.34M
Kapitalizacja rynkowa	1.75B
EPS	$0 ( 2024-03-20 )
Następna data zysków	( $0.340 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	23.63
ATR14	$0.00800 (0.05%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Tierney David S	Buy	25 000	Common stock, par value $0.001 per share
2024-04-08	Tierney David S	Sell	25 000	Common stock, par value $0.001 per share
2024-04-08	Tierney David S	Buy	25 000	Options to purchase common stock
2024-03-27	Elsbernd Brian	Sell	25 000	Common stock, par value $0.001 per share
2024-02-15	Del Carmen Jeffrey	Sell	10 667	Restricted Stock Units

INSIDER POWER
37.04
Last 100 transactions
Buy: 3 182 900 \| Sell: 1 448 545

Wolumen Korelacja

Długi: -0.46 (neutral)

Krótki: -0.52 (weak negative)

Signal:(47.337) Neutral

Catalyst Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje
PMTS	0.897
KPTI	0.88
AVID	0.873
PRAA	0.854
FCCO	0.852
BNIXU	0.849
PINC	0.848
KTCC	0.844
PARA	0.843
DTEA	0.838

10 Najbardziej negatywne korelacje
CVGI	-0.927
CRSP	-0.915
NNOX	-0.915
POWL	-0.914
ADMS	-0.914
FTDR	-0.912
MDXG	-0.912
FLGC	-0.905
CNCE	-0.905
RESN	-0.904

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Catalyst Pharmaceuticals Korelacja - Waluta/Towar

0.31
( neutral )

0.54
( weak )

0.00
( neutral )

-0.32
( neutral )

0.00
( neutral )

0.72
( moderate )

Catalyst Pharmaceuticals Finanse

Annual	2023
Przychody:	$398.20M
Zysk brutto:	$313.67M (78.77 %)
EPS:	$0.670

FY	2023
Przychody:	$398.20M
Zysk brutto:	$313.67M (78.77 %)
EPS:	$0.670

FY	2022
Przychody:	$214.20M
Zysk brutto:	$179.81M (83.94 %)
EPS:	$0.800

FY	2021
Przychody:	$140.83M
Zysk brutto:	$118.95M (84.46 %)
EPS:	$0.380

Financial Reports:

No articles found.

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.